Chronic lacrimal sacculitis is a common eye disease caused by obstruction or narrowing of the nasolacrimal duct, with lacrimation and pus as the main clinical symptoms. The treatment of chronic dacryocystitis is not effective with medication alone because the obstruction of the lacrimal duct is not resolved, and surgical treatment to open the obstructed nasolacrimal duct is the key to treat chronic dacryocystitis. The commonly used procedure is nasolacrimal duct anastomosis. The traditional surgery is external nasolacrimal duct anastomosis through skin incision, which requires incision on the face and removal of part of the nasal bone, which is more traumatic and leaves facial scar, while the micro-innovation technology – nasal endoscopic internal nasolacrimal duct anastomosis, which does not require incision on the face and does not leave facial scar, is minimally invasive, safe and has a high cure rate, and is highly recognized by patients as It is the most advanced cosmetic lacrimal surgery at present. The advantages of nasal endoscopic nasal lacrimal sac anastomosis micro-innovation technology: 1, is a minimally invasive surgery, tissue damage is small, avoid facial incision, no facial scars, does not affect the aesthetic. 2.Surgery under the guidance of nasal endoscope, with clear vision of high definition picture, to achieve fine and accurate results with high safety. 3.Surgery time is short, minimally invasive, less bleeding, fast post-operative recovery, and no major impact on patients’ daily life. 4.The efficacy is reliable, the cure rate is high, and the treatment of dacryocystitis and lacrimal duct obstruction is an advanced treatment mode at this stage.